Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiation OncologyAetna Cryoablation Coverage & Prior Auth Update | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0100

    Cryoablation

    Customize your policy alerts

    Sign up for Aetna Policy 0100 alerts

    Get alerted when Policy 0100 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This Aetna clinical policy governs indications, coverage determinations, and coding for cryoablation procedures across a range of conditions and who is affected (members receiving cryoablation).

    Policy Summary
    PayerAetna
    PolicyCryoablation
    Policy CodePolicy 0100
    Change TypeNo material change
    Effective DateDec 6, 1995
    Last ReviewAug 4, 2026
    Next Review DateJan 28, 2027
    Key ActionObtain prior authorization and document indication, lesion size/number, prior therapies or inoperability, and required imaging when submitting for cryoablation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20+medically necessary indications listed
    49+experimental / investigational indications listed
    multiplecode groups provided
    <=4 cmrenal/adrenal size limit referenced
    97%technical success reported
    6%major complication rate reported

    Coverage Criteria for Cryoablation

    Medically Necessary Indications

    Covered when ANY of the following indications apply:

    Medically necessary indications list: Cryoablation is medically necessary for any of the following indications: adrenal gland metastases (up to 4 cm); cervical intraepithelial neoplasia; cryoablation of the prostate for localized prostate cancer (primary therapy alternative for T1–T3 disease) or salvage after radiation failure; renal mass (see renal mass conditional criteria); cryoablation for atrial fibrillation with localized site(s) of origin when drug-resistant/intolerant or patient declines long-term drug therapy (e.g., pulmonary vein isolation); desmoid tumor (aggressive fibromatosis); esophageal dysplasia; fibro-adipose vascular anomaly (FAVA) lesions; low-risk superficial basal cell carcinoma and squamous cell carcinoma in situ (Bowen disease) when surgery or radiation is contraindicated or impractical; malignant endobronchial obstruction; metastatic hemangiopericytoma to lung when not a surgical candidate with <5 metastases each <3 cm; osteoid osteoma after failure of salicylates/NSAIDs; painful bone metastases ≤2 cm; and painful vascular tumors (epithelioid hemangiomas).see children

    List reflects Aetna policy enumerated indications (selection).

    Renal Mass — Conditional Criteria

    Cryoablation of a renal mass (confirmed or suspected renal cell carcinoma) ≤4.0 cm is medically necessary when ANY one of the following alternative criteria is met:

    Policy Summary
    PayerAetna
    PolicyCryoablation
    Policy CodePolicy 0100
    Change TypeNo material change
    Effective DateDec 6, 1995
    Last ReviewAug 4, 2026
    Next Review DateJan 28, 2027
    Key ActionObtain prior authorization and document indication, lesion size/number, prior therapies or inoperability, and required imaging when submitting for cryoablation.
    SourceLink
    On This Page
    Coverage Criteria for CryoablationCoding and Code-Based LimitsProvider Actions, Authorization & DocumentationBackground and Evidence SummariesDefinitions & Key TermsPolicy Revision History
    Renal mass criteria: 1) The person is a high‑risk surgical candidate; OR 2) The person has renal insufficiency defined as GFR ≤ 60 ml/min/1.73 m2; OR 3) The person has a solitary kidney.GFR ≤60 ml/min/m2

    Tumor size limit for this covered indication is up to 4 cm; selection based on inability or high risk for nephrectomy; percutaneous approach and need for biopsy and imaging follow-up described in supporting literature.

    Clinical indications discussed

    Contextual clinical indications and study-based observations summarized from the evidence (background; not an exhaustive coverage rule):

    Prostate cancer context: Cryosurgical ablation is recognized as an accepted management option for localized prostate adenocarcinoma (AUA statement), though long-term curative efficacy is not fully established and patients should be counseled on alternate treatments.

    Background guidance; informs counseling and selection, not an additional criterion.

    Endobronchial obstruction (palliation): Bronchoscopic cryotherapy/cryodebridement has been reported to restore airway patency and provide symptom relief in many patients with malignant central airway obstruction in retrospective series; procedure success and bleeding risk factors are described in observational studies.

    Evidence mainly retrospective; useful for palliation when indicated.

    Renal masses (alternative to surgery): Percutaneous and laparoscopic cryoablation are described as options for small renal masses in patients who are poor surgical candidates, with encouraging short- to mid-term technical success but limited long-term oncologic data.tumor size up to ~4 cm per guidance

    NICE and other reviews note limited long-term evidence and recommend use with audit or research arrangements for some patients.

    Renal cancer — small tumors

    Summary of coverage‑relevant findings for small renal tumors (background evidence and size limits):

    Renal cancer (small renal masses): Cryoablation may be an option for small (stage I) renal tumors for elderly, infirm, or otherwise inoperable patients; imaging-based radiographic success correlates well with histology in cryoablation series; NICE guidance suggests a maximum recommended renal tumor size of approximately 4 cmtumor size <= ~4 cm

    Short-term outcomes compare favorably to laparoscopic approach; long-term efficacy and pathological confirmation may be limited; hemorrhage associated with multiple probes.

    Breast fibroadenomas

    Evidence and limits for cryoablation of breast fibroadenomas (background):

    Breast fibroadenomas: Cryoablation for breast fibroadenomas produces substantial volume reduction and favorable cosmetic outcomes in small series and is FDA‑cleared for fibroadenoma in some devices; however, long-term comparative effectiveness versus surgical excision and limitations related to lack of histologic specimen remain concerns and evidence is limited by incomplete follow-up in many series.no numeric threshold specified

    Procedure has been implemented by some breast-surgery groups but comparative randomized data are lacking.

    Atrial fibrillation

    Summary of atrial fibrillation indications and evidence supporting surgical and catheter cryoablation:

    Atrial fibrillation: Cryoablation (surgical lesion sets and catheter-based cryoballoon pulmonary vein isolation) is effective for rhythm control in many series; guideline recommendations support catheter ablation for symptomatic paroxysmal AF refractory to antiarrhythmic drugs and do not distinguish RF from cryoablation. Clinical contexts include concomitant surgical procedures (maze/linear lesions) and standalone PVI for drug-refractory symptomatic AF.clinical indication: symptomatic paroxysmal AF after failed AAD therapy

    Evidence includes randomized and multicenter studies (e.g., STOP‑AF) and consensus guideline endorsements.

    Skin, sarcoma, desmoid tumors, and other uses

    Other and less-established uses summarized from the evidence (background):

    Skin, sarcoma, desmoid tumors, and other uses: Cryosurgery/cryotherapy has limited role for low‑risk superficial basal cell carcinoma and Bowen disease when surgery/radiation are contraindicated; cryoablation has been used for symptomatic metastatic soft‑tissue sarcoma, desmoid tumors, and selected soft‑tissue lesions with case‑series evidence supporting local control in small‑to‑moderate sized tumors, but evidence is heterogeneous and limited.case-by-case; often palliative or when other therapies have failed

    Evidence for larger tumors or certain indications (e.g., plantar fibroma) is insufficient and not recommended.

    Evidence summaries (no explicit coverage rules)

    Evidence summaries relevant to coverage considerations (narrative evidence items; not prescriptive coverage logic):

    Small series and feasibility evidence: Multiple small series and preliminary studies report technical feasibility, symptomatic benefit, and local tumor control for diverse indications (e.g., desmoid tumors, esophageal carcinoma refractory to conventional therapy, medically inoperable stage I NSCLC, retroperitoneal sarcoma), but authors repeatedly call for larger controlled studies.

    These observations inform situational coverage decisions and highlight evidence limitations.

    Comparative evidence signals: Randomized evidence in other procedural domains (e.g., cryo‑stripping vs conventional GSV stripping) sometimes favors conventional approaches, indicating indication‑specific comparative data are important for policy decisions.

    Helps identify indications where cryoablation is not favored based on RCTs.

    Effectiveness in CIN: Meta-analysis of cryotherapy for cervical intraepithelial neoplasia shows high cure rates supporting cryotherapy effectiveness in that setting, particularly using double‑freeze techniques and when endocervical involvement is absent.CIN cure rates: CIN1 94%, CIN2 92%, CIN3 85%

    Supports coverage of cryotherapy for CIN where clinically appropriate.

    PNN cryoablation — evidence-based outcome criteria

    Outcome thresholds and responder definitions derived from randomized and pooled analyses for posterior nasal nerve (PNN) cryoablation:

    PNN cryoablation effectiveness indicators: Randomized evidence demonstrates superiority to sham with responder definition of ≥30% reduction in rTNSS at 90 days (73.4% active vs 36.5% sham); systematic reviews/meta-analyses report pooled clinically significant reductions in rTNSS (~3.5 points) and responder rates around 71% with benefits persisting up to 12 months in many studies.>=30% rTNSS reduction for responder; mean rTNSS change approx -3 to -3.5

    Durability beyond 12 months is less certain; trial designs and follow-up vary.

    Other indications with limited supportive evidence

    Other indications supported by limited or preliminary evidence (background summaries):

    Cancer pain: Systematic review across heterogeneous studies (n≈496 patients) reports large reductions in pain scores and opioid use after cryoablation for cancer‑related pain, but evidence is nonrandomized and heterogeneous.clinical pain reductions reported from 24 hours to 6 months

    May support palliative use in select patients with documented opioid/pain reduction goals.

    FAVA lesions: Small retrospective cohorts (n≈20) report technical success and significant pain improvement after percutaneous cryoablation for FAVA lesions; follow-up is short and findings need validation.improvement in BPI scores at 2–5 months

    Evidence is preliminary.

    Hepatocellular carcinoma and liver metastases: Cryoablation has historical use for HCC with some series reporting 5‑year survival, but lacks randomized comparative data and may have high complication rates; generally not first‑line and reserved for select situations.5‑year survival reported in some series ~39.8%

    Cochrane review concluded insufficient RCT evidence to establish benefit over surgery.

    Osteoid osteoma: Phase‑I trial (n=9) of percutaneous cryoablation showed marked pain reduction and safety, supporting feasibility pending larger trials.marked NRS reduction to near zero by 1 year

    Preliminary evidence only.

    Selection and procedural factors

    Selection and procedural factors associated with more favorable outcomes (study‑derived observations):

    Favorable patient/procedure selection: Best outcomes reported when patients have limited pulmonary metastases (commonly 1–5 or 1–6 lesions) with maximal lesion diameter generally ≤3.5 cm and often ≤1.5–2.0 cm; smaller lesion diameter associated with improved local progression‑free intervals.lesion_count<=6; lesion_diameter<=3.5cm; best outcomes <=1.5–2.0 cm

    Multiple prospective studies use these enrollment limits.

    Procedural factors linked to efficacy: Appropriate probe number, CT guidance, and multi‑cycle freeze‑thaw protocols (double or triple freeze) were commonly used and associated with technical success in series.

    Hemorrhage risk increased with multiple probes in some renal series.

    Risk factors for worse outcomes/complications: Tumor diameter >3 cm associated with higher local progression; pneumothorax requiring intervention common in pulmonary procedures (rates variable up to ~26% requiring pleural catheter), and prior local therapy or complex anatomy increases complication risk.tumor_diameter>3cm; pneumothorax intervention rates up to ~26%

    Consider proximity to critical structures (contraindication within ~1 cm).

    Evidence-based candidate and context observations

    Evidence-based candidate characteristics and situational observations from trials and series (background):

    Breast cryoablation candidate characteristics: ICE3 and pooled analyses enrolled mainly older patients with unifocal, ultrasound‑visible invasive ductal carcinoma ≤1.5 cm (ICE3) or ≤20 mm (meta‑analysis), grade 1–2, HR‑positive, HER2‑negative; studies emphasize documented follow‑up and consideration of adjuvant endocrine therapy in selected patients.tumor size <=1.5 cm (ICE3) or <=20 mm (meta-analysis)

    Nonrandomized designs limit generalizability; FDA premarket authorization exists for a narrow elderly, low‑risk population.

    Intercostal nerve / SSRF analgesia context: Cryoablation of intercostal nerves has been used intraoperatively with SSRF or thoracoscopic approaches to reduce postoperative pain and opioid use in some cohorts; results are mixed and evidence includes retrospective cohorts and pilot studies.none

    Considered investigational in some contexts pending larger trials.

    Venous malformations: Small case series and systematic reviews report substantial lesion volume reduction and pain improvement after percutaneous cryoablation for venous malformations; data are limited in size and heterogeneity.none

    Technical success commonly reported in small studies.

    Endoscopic balloon cryoablation for bladder/other early data: Phase‑II randomized data suggest potential benefit for balloon cryoablation in select bladder settings, but guideline adoption is pending and further validation is required.none

    Situational/experimental in many guideline contexts.

    Evidence summaries and situational coverage considerations

    Situational considerations and evidence summaries informing coverage decisions (background narrative):

    Breast cancer — investigational and authorized contexts: Meta‑analysis and trial data report low pooled local recurrence for cryoablation of small breast cancers (pooled recurrence ~1.1% for tumors ≤20 mm) and ICE3 reported favorable 5‑year IBTR in selected older patients; ProSense received FDA premarket authorization for patients ≥70 with biologically low‑risk tumors ≤1.5 cm when combined with endocrine therapy, but evidence limitations include nonrandomized designs and variable follow‑up.tumor size <=20 mm or <=1.5 cm depending on context

    Policy should differentiate narrowly authorized indications from broader investigational use.

    Thyroid cancer: Cryoablation has been used for local recurrences and metastatic cervical lymph nodes with reports of tumor involution and technical success, but longer‑term outcomes and comparative evidence are limited.variable tumor sizes reported

    May be considered in select, inoperable recurrences with documented rationale.

    Metastatic melanoma + ICI: Small nonrandomized phase‑II data in PD‑1 refractory metastatic melanoma show signals of objective response (ORR 23.5%, DCR 41%) when cryoablation is combined with continued ICI, supporting further investigation but remaining exploratory.n/a

    Combination therapy remains investigational pending larger studies.

    The policy lists numerous conditions and clinical uses for which Aetna considers cryoablation experimental, investigational, or unproven. Examples called out in the policy include cryoablation for benign prostatic hypertrophy, breast carcinoma and fibroadenoma, cancer pain, chronic headache, lipoma, plantar fibroma, metastatic hepatocellular carcinoma, neuroendocrine tumors (except selected hepatic metastases), osteoarthritis of the hip or knee, and venous malformations. The policy also enumerates many other less-established indications (e.g., abdominal wall arteriovenous malformation, endometriosis, hookworm-related cutaneous infection, idiopathic ventricular tachycardia, intercostal nerve procedures for various pain indications, and spinal giant cell tumors) and explicitly states that effectiveness for these approaches has not been established.

    The document further highlights device- or technique-specific uses considered investigational because of insufficient evidence, including cryo-nanocatalysis for solid tumors, endoluminal cryoablation for varicose veins, endoscopic balloon cryoablation for bladder cancer, Metered CryoSpray (MCS) for chronic bronchitis, and spray cryotherapy for subglottic/cervical tracheal stenosis. These listings are presented as non-exhaustive examples of investigational uses and refer the reader to supporting CPBs where applicable.

    The policy text explicitly identifies broad ICD-10 ranges of malignant neoplasms that are listed as ICD-10 codes not covered for indications listed in the CPB. Examples of these non-covered ranges include malignant neoplasms of the lip/oral cavity/pharynx (C00–C14.8), digestive organs (C15–C26.9), respiratory and intrathoracic organs (C30–C39.9), bone and articular cartilage (C40–C41.9), breast (C50.011–C50.A2), female genital organs (C51–C58), male genital organs (C60–C63.12), urinary tract (C64–C68.9), eye/brain/CNS (C69–C72.59), thyroid and endocrine glands (C73–C75.9), and other specified/unspecified neoplasm categories (C76–C80.2), among others.

    The document frames these ICD-10 ranges as diagnoses for which cryoablation-related CPT/HCPCS codes are designated not covered for the indications listed in the policy, and it instructs providers to verify code-specific coverage prior to scheduling procedures.

    The policy notes that there is little evidence supporting cryoablation for large renal masses and that use for some benign musculoskeletal conditions (for example, plantar fibroma) is not recommended in the absence of peer‑reviewed data. NICE and other reviews cited in the policy emphasize that cryotherapy for renal cancer has inadequate long‑term evidence for use beyond select, small tumors and should be used with special arrangements for consent, audit, or research when applied outside established indications.

    For plantar fibroma and other conditions without peer‑reviewed clinical series, the policy explicitly states that cryoablation is not recommended due to the lack of supportive evidence.

    A randomized, multi‑center trial comparing cryo‑stripping of the great saphenous vein with conventional stripping demonstrated higher rates of residual GSV at 6 months and no quality‑of‑life advantages for cryo‑stripping. The study’s findings indicate procedural inferiority of cryo‑stripping versus conventional stripping and support the policy’s implication that cryo‑stripping is not favored for management of varicose GSV disease.

    The policy references contemporary UpToDate reviews to note the absence of cryoablation or cryotherapy for certain conditions. Specifically, UpToDate summaries for chronic daily headache and for hookworm-related cutaneous infections do not list cryoablation or cryotherapy as therapeutic options, implying a lack of evidence supporting these applications.

    Aetna cites multiple reviews and series concluding that cryotherapy/cryablation for liver metastases (including colorectal liver metastases and metastatic hepatocellular carcinoma) has insufficient evidence of benefit compared with conventional surgery or other established local therapies. UpToDate and a Cochrane review are referenced, noting that cryotherapy is now rarely used for liver metastases given the availability of newer and safer modalities and that RCT evidence of survival or recurrence benefit is lacking.

    Because of these evidence limitations, the policy indicates that cryoablation for hepatic metastases is not supported as a routine first‑line therapy and should be considered only in select, special situations where other modalities are not suitable.

    The policy emphasizes that systematic reviews and guideline summaries have concluded insufficient evidence to determine whether cryotherapy for liver metastases provides meaningful survival or recurrence benefits compared with conventional surgical approaches. As a result, cryoablation is rarely considered first‑line for hepatic metastases and is reserved for selected situations, if at all.

    A recurrent limitation across many indications is that supporting studies are small, retrospective, and heterogeneous. The policy notes that evidence for numerous uses (for example, desmoid tumors, venous malformations, FAVA, and combination cryoablation with cementoplasty for large pelvic metastases) is limited to small case series or retrospective cohorts with variable follow‑up, prior therapies, and outcome definitions. These methodological limitations reduce the strength of evidence for routine coverage and prompt the policy to classify many such uses as investigational or to require more rigorous data.

    When positive outcomes are reported in these small series, authors frequently call for larger, controlled trials before broader adoption.

    The policy identifies tumor size as a key predictor of local progression: multiple series and multivariate analyses show that larger tumors (notably >3 cm) are associated with an increased risk of local progression and higher complication rates, making them less suitable candidates for percutaneous cryoablation as a standalone therapy.

    For pulmonary and other metastatic lesions, the policy and cited studies indicate improved outcomes with smaller lesion diameters, reinforcing size‑based selection thresholds used in the policy and clinical series.

    The policy treats spray cryotherapy (noncontact liquid nitrogen spray) for airway lesions as investigational in light of reported serious complications in case series and reviews. UpToDate and cited series report adverse events including barotrauma, gas embolism, cardiopulmonary instability, airway perforation, and death; one study reported a 19% overall complication rate despite high technical success, leading the authors and the policy to recommend that spray cryotherapy be used only in investigational settings.

    Because of these safety concerns and the limited quality of evidence, spray cryotherapy for central airway disease is not considered standard therapy and requires investigational oversight when used.

    The policy states that ablative techniques, including cryoablation, are contraindicated when the target tumor lies within 1 cm of critical structures such as the spinal cord, major nerves, and large blood vessels. This restriction reflects safety considerations cited in spine and other series where proximity to critical anatomy increases the risk of neurologic injury or vascular complication.

    This proximity‑based contraindication is applied consistently in the document as a procedural safety criterion that would preclude use of percutaneous cryoablation in those anatomic circumstances.

    The policy notes that the NCCN Bone Cancer guideline (Version 3.2023) does not mention cryoablation as a management option for bone cancer. This absence of guideline endorsement is presented as a contextual observation supporting the limited or experimental status of cryoablation for many bone tumor indications within the policy.

    Similarly, the policy highlights that the NCCN Bladder Cancer guideline (Version 3.2023) does not reference endoscopic balloon cryoablation as a management option. The absence of mention in major guideline documents is used throughout the policy to indicate that certain cryoablation techniques remain investigational pending further evidence or guideline adoption.

    Major guidelines and contemporary reviews cited in the policy generally do not include cryoablation as a management option for several conditions. Examples called out include osteoarthritis of the hip/knee, osteoblastoma, Rosai‑Dorfman disease, and small cell lung cancer, where UpToDate or NCCN guideline excerpts do not list cryoablation as a standard therapeutic approach.

    The document uses these guideline omissions to underscore that cryoablation is not established for these indications and that additional high‑quality evidence would be required for guideline incorporation and routine coverage.

    Where the policy excerpts present preliminary or small, nonrandomized studies (for example, MCS for chronic bronchitis), the narrative frequently notes limitations of the evidence—small sample sizes, single‑arm designs, lack of blinding or control groups, incomplete follow‑up, and absence of confirmatory histologic endpoints. These limitations are called out but are not always translated into explicit coverage exclusions in the reference excerpts.

    As a result, the policy frequently designates such uses as investigational and indicates that further randomized controlled trials are needed to establish safety and efficacy before routine clinical use can be supported.

    The policy’s reference sections include numerous citations but the document excerpts in this portion do not list additional explicit coverage exclusions beyond those already summarized; instead, they provide supporting literature and note evidence limitations for many of the investigational uses described.

    Coding and Code-Based Limits

    Covered CPT Codes (if selection criteria are met)CPTCovered
    0441TAblation, percutaneous, cryoablation, includes imaging guidance, lower extremity distal/peripheral nerve.
    20983Ablation therapy for reduction or eradication of 1 or more bone tumors (eg, metastasis) including adjacent soft tissue when involved by tumor extension, percutaneous, including imaging guidance when performed; cryoablation.
    31641Bronchoscopy (rigid or flexible); with destruction of tumor or relief of stenosis by any method other than excision (e.g., laser therapy, cryotherapy).
    32994Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, including imaging guidance when performed, unilateral; cryoablation.
    50250Ablation, open, 1 or more renal mass lesion(s), cryosurgical, including intraoperative ultrasound guidance and monitoring, if performed.
    50593Ablation, renal tumor(s), unilateral, percutaneous, cryotherapy.
    55873Cryosurgical ablation of the prostate (includes ultrasonic guidance for interstitial cryosurgical probe placement).
    57511Cautery of cervix; cryocautery, initial or repeat.
    67101Repair of retinal detachment, including drainage of subretinal fluid when performed; cryotherapy.
    67107Repair of retinal detachment; scleral buckling, including cryotherapy.
    1–10 of 17
    1/2
    CPT Codes not covered for indications listed in the CPBCPTNot Covered
    0581TAblation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance when performed, unilateral.
    1040TBronchoscopy, flexible, with bronchial cryotherapy, 1 lung, including trachea, when performed.
    19105Ablation, cryosurgical, of fibroadenoma, including ultrasound guidance, each fibroadenoma.
    32998Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, radiofrequency, unilateral [cryoablation for nonobstructive non-small cell lung cancer].
    HCPCS codes not covered for indications listed in the CPBHCPCSNot Covered
    C9808Nerve cryoablation probe (e.g., cryoice, cryosphere, cryosphere max, cryoice cryosphere, cryoice cryo2), including probe and all disposable system components, non-opioid medical device.
    C9809Cryoablation needle (e.g., iovera system), including needle/tip and all disposable system components, non-opioid medical device.
    C1886Catheter; extravascular tissue ablation, any modality.
    C2618Probe/needle, cryoablation.
    ICD-10 codes covered if selection criteria are metICD-10Covered
    C61Malignant neoplasm of prostate.
    C64.1 - C64.9Malignant neoplasm of kidney, except renal pelvis.
    C34.00 - C34.92Malignant neoplasm of bronchus and lung (used in context of malignant endobronchial obstruction).
    D06.0 - D06.9Carcinoma in situ of cervix uteri (CIN III).
    K22.710 - K22.719Barrett's esophagus with dysplasia.
    D04.0 - D04.9Carcinoma in situ of skin (Bowen disease).
    ICD-10 codes not covered for indications listed in the CPBICD-10Not Covered
    C15.3 - C15.9Malignant neoplasm of esophagus (listed as ICD-10 not covered for cryoablation).
    C50.011 - C50.A2Malignant neoplasm of breast (not covered).
    D17.0 - D17.9Lipoma (not covered).
    G44.021 - G44.029Chronic cluster headache (not covered).
    ICD-10 codes listed in policy excerptsICD-10
    D17.0 - D17.9Lipoma
    D21.0 - D21.9Other benign neoplasm of connective and other soft tissue
    D24.1 - D24.9Benign neoplasm of breast
    D33.3Benign neoplasm of cranial nerves
    G44.021 - G44.029Chronic cluster headache
    G56.00 - G57.93Mononeuropathies
    I80.00 - I80.3Phlebitis and thrombophlebitis of superficial and deep vessels of lower extremities
    I82.401 - I82.4Z9Acute embolism and thrombosis of deep veins of lower extremity
    J30.0 - J30.9Vasomotor and allergic rhinitis
    M17.0 - M17.9Osteoarthritis of knee
    1–10 of 17
    1/2
    Codes mentioned or impliedmixed
    No codes listed
    Codes referenced in this sectionmixed
    no explicit CPT/HCPCS/ICD codes listed in these chunksDocument excerpts do not include specific billing codes
    Lesion size threshold — adrenal gland and renal masses up to 4 cm
    Adrenal & renal mass size limitUp to 4 cm maximum diameter for adrenal gland metastases and renal masses when covered indications apply
    Renal mass contextCryoablation for renal masses is limited to confirmed or suspected RCC with size ≤4 cm when selection criteria are met (see renal conditional criteria)
    Exception—larger reported seriesSome renal series report tumors >4 cm (mean sizes up to 3.3 cm and ranges to 7.3 cm) but policy limit remains ≤4 cm for coverage
    Pulmonary metastatic lesions — 6 or fewer lesions, each <4 cm when not surgical candidate
    Lesion count and size for pulmonary metsUp to 6 lesions (policy: 6 or less) acceptable when member is not a surgical candidate; each lesion <4 cm
    Trial enrollment size limitProspective trials commonly enrolled patients with metastases ≤3.5 cm maximal diameter (de Baere / Callstrom inclusion criteria)
    Typical lesion size in seriesMean metastatic lesion sizes reported around 1.0–1.4 cm in pivotal prospective series
    Painful bone metastases — lesion size ≤2 cm
    Size threshold for painful bone metastasesLesion size ≤2 cm for cryoablation of painful bone metastases
    Evidence linking size to LPFSStudies indicate BM >2 cm predict local progression; best outcomes with BM ≤2 cm
    Use in osteoid osteoma contextOsteoid osteoma trials report small nidus sizes (e.g., mean 5.9 mm) with marked pain relief after cryoablation
    Renal insufficiency threshold — GFR ≤60 ml/min/m2
    Renal insufficiency threshold (coverage criterion)Glomerular filtration rate (GFR) ≤ 60 ml/min/1.73 m2 qualifies as renal insufficiency for renal mass cryoablation criteria
    Role in renal mass decision-makingGFR ≤60 is one of three alternative (OR) criteria (others: high-risk surgical candidate or solitary kidney) permitting cryoablation for renal masses ≤4 cm
    Documentation implicationPrior authorization should document measured GFR to support eligibility
    Maximum lesion diameter for trial enrollment — <= 3.5 cm
    Maximum lesion diameter used in pulmonary trial enrollment≤ 3.5 cm maximal diameter used as an inclusion criterion in key pulmonary metastasis trials
    Typical study median/mean sizesMedian lesion sizes in trials commonly ~1.0–1.4 cm; upper enrollment limit 3.5 cm
    Documentation for authorizationPrior authorization should include lesion maximal diameter (studies enrolled up to 3.5 cm) and lesion count
    Lesion size associated with better outcomes — <= 1.5-2.0 cm associated with improved outcomes
    Lesion sizes associated with improved outcomesLesions ≤1.5–2.0 cm are associated with better local progression‑free intervals and local progression-free survival in multiple series
    Observed effect sizesdecreased local progression and higher LPFS reported for tumors ≤1.5 cm vs larger lesions (Yamauchi: markedly better LPFS for ≤1.5 cm)
    Implication for patient selectionPatients with smaller metastases (≤1.5–2.0 cm) are preferred candidates for percutaneous cryoablation given improved efficacy and lower complications

    Provider Actions, Authorization & Documentation

    Prior Authorization

    Prior authorization required for covered CPT/HCPCS when criteria apply

    Selected CPT/HCPCS codes in this policy are covered only when the applicable medical necessity selection criteria are met; use of these codes may require verification of medical necessity or prior authorization before payment. Submit documentation that demonstrates the patient meets the policy's indication-specific criteria when requesting authorization for the listed procedure codes.

    • Covered CPT codes are conditional on meeting the policy's selection criteria (see covered indications and size/count thresholds).
    • Verification of medical necessity/prior authorization is advised prior to scheduling when coverage depends on policy criteria.
    Billing Rule

    Verify code-specific coverage prior to authorization

    Providers should verify coverage for the specific CPT/HCPCS and ICD-10 codes to be used prior to authorization or scheduling; certain CPT/HCPCS and ICD-10 ranges are called out in the policy as not covered for the indications listed and use of those codes may trigger denial.

    • Reference the policy's code lists — some CPT/HCPCS codes are 'not covered for indications listed' and multiple ICD-10 malignant neoplasm ranges are listed as not covered for the indications in this CPB.
    • Confirm code-specific coverage and whether prior authorization is required before performing the procedure.
    Prior Authorization

    Indication and lesion size must be documented for authorization

    Prior authorization submissions must document the treated lesion’s indication and size — the policy restricts renal/adrenal masses to approximately ≤4 cm and notes size thresholds for other indications; authorization decisions will consider these size limits.

    • Renal mass and adrenal gland indications: tumor size up to 4 cm is specified in the policy.
    • Provide lesion location and maximal diameter as part of the request to demonstrate alignment with the policy thresholds.
    Documentation Required

    Document prior therapy attempts or inoperability rationale

    When conventional definitive therapy is available, prior authorization should include documentation of prior therapies attempted or a clear rationale why conventional therapy is not possible (for example, prior endoscopic resection/chemoradiation for esophageal cancer or inoperability/comorbidity indices for lung cancer).

    • Document prior treatments and reasons for failure or contraindication to standard therapies.
    • Include comorbidity scores or other evidence of inoperability when surgery is being declined due to risk.
    Prior Authorization

    Multidisciplinary review recommended for complex combined procedures

    For complex combined procedures (e.g., combined cryoablation and cementoplasty for large pelvic metastases), providers should document that the case was reviewed by a multidisciplinary conference or tumor board prior to referral for the combined intervention.

    • Include evidence of multidisciplinary review (participants, date, and consensus recommendation) in the authorization record.
    • Explain why combined procedure is indicated and why alternative treatments are not appropriate.
    Prior Authorization

    Prior authorization requirements for PNN cryoablation: prior medical therapy and baseline rTNSS

    Prior authorization for posterior nasal nerve (PNN) cryoablation should document prior medical management failure (minimum 4 weeks of intranasal corticosteroids per trial inclusion) and include baseline symptom scoring (e.g., rTNSS) and the intended target nerve region.

    • Document failure of at least 4 weeks of intranasal corticosteroids as part of the prior medical therapy history.
    • Include baseline rTNSS and planned target (PNN) in the authorization request; provide expected responder criteria if available.
    Documentation Required

    Document multidisciplinary review and prior therapy for combined cryoablation + cementoplasty

    When requesting authorization for combined cryoablation plus cementoplasty for large pelvic bone metastases, document multidisciplinary tumor-board review and prior failure or contraindication to surgical management or standard palliation.

    • Include documentation that the patient was referred after formal multidisciplinary conference review.
    • Document prior pain management attempts and rationale for choosing combined cryoablation and cementoplasty (e.g., lesion ≥5.0 cm, refractory pain).
    Documentation Required

    Document prior therapies and treatment intent

    Authorization requests should record prior therapies and the treatment intent (first-line vs salvage; curative vs palliative) because studies and appropriateness assessments relied on these distinctions when evaluating outcomes.

    • State whether the procedure is intended as curative or palliative.
    • List prior systemic, surgical, radiation, and local therapies with dates and outcomes.
    Prior Authorization

    Authorization must state lesion number and maximal diameter

    Prior authorization must reflect lesion count and maximal lesion diameter for metastatic indications — studies enrolling pulmonary metastasis patients used explicit limits (e.g., 1–6 or 1–5 metastases and maximal diameters up to ~3.5 cm) and authorization should match those parameters.

    • Provide number of lesions and the largest lesion’s diameter when requesting authorization for pulmonary metastasis cryoablation.
    • Indicate performance status and whether the intent is oligometastatic-directed therapy or palliative symptom control.
    Prior Authorization

    Prior authorization for pulmonary metastasis cryoablation: tumor count, size, and performance status

    For pulmonary metastasis cryoablation, prior authorization should include tumor count and maximal diameter (studies enrolled patients with up to 3.5 cm lesions and limited lesion counts) plus prior therapies and performance status to align with published trial inclusion criteria.

    • Include the planned number of metastases to be treated and the maximal diameter of each lesion.
    • Document prior systemic therapies and current ECOG/Karnofsky performance status.
    Prior Authorization

    Prior authorization for renal mass ablation: tumor and patient characteristics

    When requesting authorization for percutaneous renal mass cryoablation, provide tumor characteristics (size, imaging visibility), patient comorbidities (e.g., GFR), and the clinical rationale for ablation versus partial nephrectomy because guidelines reserve ablation for those in whom complete ablation can be achieved and who are often higher surgical risk.

    • Report tumor maximal diameter (policy specifies up to 4 cm for renal masses) and biopsy results if available.
    • Provide patient's GFR and evidence of high surgical risk or solitary kidney status when applicable.
    Documentation Required

    Document trial-derived clinical eligibility elements with authorization

    Authorization requests for investigational or study-like indications should include the clinical eligibility elements used in trials (for example, ICE3 and meta-analyses for breast cryoablation specify tumor size limits and receptor status); document that the patient meets those trial-derived eligibility criteria when applicable.

    • For breast cryoablation contexts, include tumor size, receptor status, and age criteria when claiming alignment with trial eligibility.
    • Provide supporting pathology and imaging to show eligibility parallels to published cohorts.
    Documentation Required

    Document eligibility for FDA-authorized breast cryoablation (ProSense)

    For FDA-authorized ProSense breast cryoablation, authorization should document that the patient meets the device labeling/authorization criteria (age and biologically low‑risk tumor features) and that adjuvant endocrine therapy is planned as required by the authorization.

    • Document patient age (≥70 per premarket authorization) and tumor biology (unifocal ≤1.5 cm, ER+/PR+, HER2-, Ki‑67 <15% or equivalent genomic risk profile).
    • Indicate planned adjuvant endocrine therapy in the treatment plan.
    Prior Authorization

    Prior authorization suggested for metered cryospray in chronic bronchitis

    For metered cryospray (MCS) or other chronic bronchitis cryotherapy, prior authorization may require documentation of persistent symptoms despite optimal medical therapy and adherence to the treatment protocol used in studies (three treatments spaced 4–6 weeks), including baseline and follow-up PROs.

    • Document failure of optimal medical therapy for chronic bronchitis and symptom burden despite therapy.
    • Indicate planned MCS treatment schedule consistent with studied protocols (three sessions 4–6 weeks apart) and provide baseline SGRQ/CAT/LCQ scores.
    Note

    Reference sections contain no additional prior authorization specifics

    The policy lists certain reference sections only; these reference chunks do not themselves specify prior authorization requirements — verify other policy sections for applicable authorization steps.

    • Reference sections contain citations and background only and do not define prior authorization processes.
    • Use the policy's prior authorization and coding sections for actionable requirements.
    Prior Authorization

    Renal mass permissions: cryoablation allowed for masses ≤4 cm with listed criteria

    Cryoablation of renal masses is permitted when the mass is ≤4 cm and the listed renal criteria are met (high‑risk surgical candidate, GFR ≤60 mL/min/1.73 m2, or solitary kidney); authorization should reflect those size and clinical thresholds.

    • Policy explicitly states renal mass cryoablation is medically necessary for masses up to 4 cm when one of the renal criteria is met.
    • Include GFR, solitary kidney status, or high surgical‑risk documentation with authorization.
    Step Therapy

    Consideration of standard surgical options before approving renal ablation

    Authorization reviewers should confirm that standard surgical options (partial nephrectomy) were considered or that the patient is not a suitable surgical candidate before approving ablation for small renal masses.

    • Document whether partial nephrectomy was considered and the rationale for selecting ablation instead.
    • When active surveillance is chosen, document reasons (comorbidities, limited life expectancy) supporting that approach.
    Step Therapy

    Surgical excision preferred for fit patients; document reasons for ablation

    Policy notes that for stage I kidney tumors surgical excision is preferred for patients in satisfactory condition; cryoablation may be appropriate for elderly or infirm patients or when surveillance is chosen, so provide documentation of operative risk or patient preference when seeking authorization.

    • Include documentation of patient fitness for surgery or reasons surgery is declined.
    • State whether surveillance, ablation, or surgery is being pursued and why.
    Step Therapy

    Stepwise therapy considerations: document prior standard treatments or contraindications

    Prior authorization reviewers may expect stepwise therapy documentation: cryoablation is often applied after failure of conventional therapy or for medically inoperable patients, so include prior/concurrent standard‑of‑care attempts where relevant.

    • For indications where conventional therapy exists, document prior unsuccessful standard treatments or contraindications.
    • For PNN and chronic rhinitis, document prior medical therapy courses and their duration/outcomes.
    Step Therapy

    Document failure of medical therapy (≥4 weeks INCS) before PNN cryoablation

    Studies of posterior nasal nerve cryoablation required prior failure of at least 4 weeks of intranasal corticosteroids; authorization for PNN procedures should include documentation of that medical therapy failure.

    • Document duration and response to intranasal corticosteroids and other nasal medications.
    • Provide baseline symptom scores (rTNSS) to support medical necessity.
    Step Therapy

    Step therapy consideration: require documentation of failed standard medical therapies for chronic rhinitis

    Consider requiring prior use of and inadequate response to standard medical therapies for chronic rhinitis before approving cryotherapy procedures; include trial documentation in the authorization record.

    • List medications tried (intranasal corticosteroids, ipratropium, antihistamines) and treatment durations/outcomes.
    • Attach baseline and follow-up PRO scores where available.
    Step Therapy

    Conventional surgical options should be considered before liver metastasis cryoablation

    For hepatic metastases or liver cryotherapy requests, document that conventional surgical options were considered; the Cochrane review found insufficient evidence to support routine first‑line use of cryotherapy for liver metastases.

    • Include documentation of multidisciplinary discussion and rationale if considering cryoablation for hepatic metastases.
    • State why surgery or other standard approaches are not feasible or were unsuccessful.
    Documentation Required

    Modality selection should consider prior therapies and multidisciplinary input

    Selection among ablation modalities should take prior therapies into account (e.g., prior radiation) and involve multidisciplinary input; document prior local and systemic therapies when requesting approval.

    • Provide history of prior radiation, systemic therapy, and any prior ablation attempts.
    • Document multidisciplinary discussions influencing modality selection.
    Step Therapy

    Stepwise management for small renal masses: document consideration of surveillance and partial nephrectomy

    When considering cryoablation for small renal masses, include documentation that alternative conservative management (active surveillance) or partial nephrectomy were considered and why ablation is chosen given patient fitness and tumor characteristics.

    • State why partial nephrectomy is not suitable or why surveillance is inappropriate for the individual patient.
    • Include biopsy results when they may change management decisions.
    Documentation Required

    Documentation must support selected indication and size/clinical criteria

    Clinical documentation supporting authorization must demonstrate that the selected medically necessary indication and any stated size or clinical criteria (e.g., lesion size ≤4 cm; GFR threshold) are met.

    • Attach imaging reports showing lesion size and location.
    • Include relevant laboratory values (e.g., GFR) and pathology when available.
    Documentation Required

    Imaging and biopsy documentation required to support technical success and follow-up

    Provide contrast-enhanced CT or MRI imaging to document baseline lesion characteristics and, when indicated, consider biopsy when results may alter management; absence of contrast enhancement post‑ablation is used to define radiographic success in many series.

    • Include pre-procedure contrast-enhanced imaging demonstrating lesion size and suitability for ablation.
    • Post-procedure imaging (CE‑MRI or CT) and, when performed in studies, biopsy results demonstrating absence of viable tumor should be included in follow-up documentation.
    Documentation Required

    Document post-procedure follow-up imaging and biopsy when performed

    Post-procedure follow-up imaging (contrast-enhanced MRI or CT) should be documented to define radiographic success; some investigators recommend follow-up biopsy in specific circumstances to confirm absence of viable tumor.

    • Report timing and findings of post-ablation contrast-enhanced imaging (commonly at ~1 month and then periodically per study protocols).
    • When biopsy is performed to confirm ablation, include pathology results in the medical record.
    Documentation Required

    Procedure and clinical baseline documentation required

    Authorization and medical records should include procedural and baseline clinical details: tumor stage, imaging guidance used, prior treatments, comorbidity status (e.g., Charlson index), and pulmonary function when relevant for thoracic procedures.

    • Provide pre-procedure performance status (ECOG/KPS), comorbidity indices, and pulmonary function test results when applicable.
    • Describe imaging guidance modality and number/type of cryoprobes planned or used.
    Documentation Required

    Document multidisciplinary review and non‑surgical candidacy for large pelvic metastasis procedures

    For patients undergoing non-surgical interventions such as combined cryoablation and cementoplasty for large pelvic metastases, document multidisciplinary review confirming non‑surgical candidacy and the reasons surgery is not an option.

    • Include tumor board notes describing deliberations and consensus.
    • Attach documentation demonstrating that the patient was judged not to be a surgical candidate.
    Documentation Required

    Required clinical documentation: baseline and follow-up symptom scores for PNN/chronic rhinitis

    Authorization requests should include baseline and follow-up validated symptom scores (e.g., rTNSS, RQLQ, NOSE) and prespecified responder definitions for PNN or other symptom-focused cryoablation indications.

    • Include baseline rTNSS and planned follow-up intervals and responder criteria (e.g., ≥30% rTNSS reduction at 90 days in RCTs).
    • Provide documentation of adverse events and medication usage changes in follow-up.
    Documentation Required

    Procedure and outcome documentation: include lesion, anesthesia, complications, and short‑term control

    Document procedural details and outcomes when submitting claims for pulmonary or adrenal cryoablation, including lesion size, number, primary tumor type, performance status, anesthesia used, immediate complications (e.g., pneumothorax and whether chest tube/pleural catheter was required), and short‑term local control outcomes.

    • Report occurrence and management of pneumothorax and other immediate complications.
    • Provide short-term local control data (e.g., imaging results at 6–12 months) when available.
    Documentation Required

    Document follow-up imaging schedule and results used to assess local control

    Follow-up imaging intervals and content used in clinical series should be documented (for pulmonary metastases studies, CT at ~1 month and then every 3–4 months was used to assess local control); include this follow-up schedule and results when available.

    • State the follow-up imaging modality and schedule used for the patient.
    • Include results of each follow-up imaging encounter to support claims of local control or need for retreatment.
    Documentation Required

    Include trial-relevant lesion counts and size limits when applicable

    Clinical trial inclusion criteria commonly used in cryoablation studies (e.g., 1–6 pulmonary metastases, maximal diameter ≤3.5 cm) are useful guides for documentation; include these elements in authorization requests when invoking trial‑based evidence.

    • When relying on trial evidence, specify how the patient meets the trial's lesion count and size eligibility.
    • Provide ECOG/KPS and other trial‑relevant baseline measures if available.
    Documentation Required

    Documentation for renal masses: biopsy and rationale for ablation vs surveillance/surgery

    For small renal masses, include biopsy results when they may alter management decisions and document consideration of active surveillance in patients with significant comorbidities or limited life expectancy.

    • Attach biopsy pathology if obtained and state whether results influenced treatment choice.
    • Document rationale for ablation versus surveillance or partial nephrectomy.
    Documentation Required

    Document patient selection criteria and procedural details referenced in studies

    Studies and series emphasize patient selection criteria (age, tumor size, histologic features, prior treatments) — document these patient-specific factors and procedural details when requesting authorization so reviewers can assess alignment with published evidence.

    • Provide age, tumor histology, receptor status (for breast), and prior treatment history in the authorization packet.
    • Include procedural details such as number of freeze cycles and imaging follow‑up plan.
    Documentation Required

    Document prior therapy and outcome measures for chronic bronchitis / MCS protocols

    Providers should document completion of prior optimal medical therapy and outcome measures for chronic bronchitis/MCS protocols (completion of serial MCS treatments and baseline/follow-up PROs) when requesting authorization or submitting claims.

    • Indicate whether the patient completed three MCS treatments and provide SGRQ/CAT/LCQ baseline and follow-up scores.
    • Document adverse events and any reasons for incomplete treatment if applicable.
    Denial Risk

    Use of 'not covered' CPT/HCPCS codes may trigger denial

    Use of CPT/HCPCS codes that are designated 'not covered' for the policy’s listed indications may trigger claim denial; confirm the correct code group and coverage status before billing.

    • Do not submit claims using codes listed as 'not covered for indications listed' in the policy for those indications.
    • If uncertain, verify coding guidance with the payer prior to submission to avoid denials.
    Denial Risk

    Not-covered ICD-10 malignant neoplasm ranges — risk of denial

    The policy enumerates malignant neoplasm ICD-10 ranges (e.g., C00–C80.2 and related ranges) that are noted as 'not covered for indications listed' in this portion of the document; using ICD-10 codes within these ranges for the listed indications could result in denial.

    • Verify that the diagnosis code you plan to bill is included in the policy’s covered ICD-10 list for the specific cryoablation indication.
    • Avoid using ICD-10 codes listed as not covered for the policy’s indications to reduce claim denials.
    Denial Risk

    Risk of denial for renal tumor size outside ~4 cm limit

    Cryoablation for renal tumors outside the policy's recommended size limits (approximately >4 cm) lacks supportive evidence in the document; authorization for larger renal masses may be unsupported and risk denial.

    • Provide strong justification and multidisciplinary review documentation if proposing ablation for renal tumors >4 cm, understanding this may be outside typical policy permissions.
    • Include imaging and rationale demonstrating why alternative options are not feasible.
    Denial Risk

    Incomplete treatment or follow‑up may adversely affect authorization

    Incomplete courses of treatment or incomplete follow-up (as occurred in some series) may limit evidence of benefit and could affect authorization for repeat or continued procedures; include documentation of completed treatment regimen and follow-up where applicable.

    • If prior series were not completed or follow-up was incomplete, explain how the current plan ensures adequate completion and follow-up.
    • Attach records of completed prior treatments and follow-up imaging or symptom assessments.
    Denial Risk

    Guideline divergence (e.g., metastases) may increase denial risk

    Lack of guideline support for certain uses (for example, cryoablation of metastases in the NCCN kidney cancer guideline) may lead to higher scrutiny or denial for those metastatic indications; document multidisciplinary rationale and evidence when seeking approval.

    • Provide guideline references and an explanation of why cryoablation is being considered despite limited guideline endorsement.
    • Include tumor board recommendations and patient-specific considerations supporting the approach.
    Denial Risk

    Durability evidence limitations may affect coverage decisions

    Insufficient long‑term durability or limited follow-up in the evidence base may lead to coverage denial where long-term benefit is required; provide available long-term outcomes or a plan for surveillance when requesting authorization.

    • When citing trial evidence, include available follow-up duration and relevant long‑term outcome data.
    • If long-term data are limited, clarify how follow-up will be performed and reported.
    Denial Risk

    Insufficient evidence for hepatic metastases — may lead to denial

    A Cochrane review concluded there is insufficient evidence to determine benefit of cryotherapy for liver metastases compared with conventional surgery; authorization for hepatic metastasis cryoablation may therefore be denied or given higher scrutiny.

    • Provide justification and multidisciplinary documentation if considering cryoablation for hepatic metastases given lack of supportive comparative evidence.
    • Consider alternative standard treatments and document why they are unsuitable for the patient.
    Denial Risk

    Combined-procedure evidence limitations — document rationale to support authorization

    Findings from combined-procedure series (e.g., cryoablation plus cementoplasty) may be confounded by the combined intervention and retrospective designs; document the rationale, expected benefit, and multidisciplinary consensus when requesting authorization for combined approaches.

    • Explain how the combined approach is expected to benefit the patient beyond single‑modality therapy.
    • Attach tumor board notes and evidence supporting the combined intervention in similar clinical scenarios.
    Denial Risk

    Complication documentation (e.g., pneumothorax) required — complications may affect coverage

    Document and manage common procedural complications (e.g., pneumothorax requiring chest tube or pleural catheter) and include their occurrence and management in the medical record, as complications can impact post‑procedure coverage decisions.

    • Report any pneumothorax, whether chest tube or pleural catheter was required, and include related inpatient or outpatient management notes.
    • Include documentation of complication resolution to support ongoing coverage.
    Denial Risk

    Contraindicated proximity to critical structures (within 1 cm) — do not request ablation

    Ablative techniques are contraindicated when a tumor is located within 1 cm of critical structures (such as the spinal cord, major nerves, or major vessels); in such situations do not request authorization for cryoablation and document the contraindication.

    • Include imaging demonstrating lesion distance from critical structures; if <1 cm, document that ablative therapy is contraindicated.
    • Provide alternative management plans if ablation is contraindicated.
    Denial Risk

    Evidence limitations for some indications may lead to denial or restriction

    Evidence limitations (small, nonrandomized, single-arm studies and subjective outcomes) noted for several indications (e.g., metered cryospray) may trigger coverage denial or restriction; include robust objective data and multidisciplinary justification to support authorization requests for these indications.

    • Provide objective outcome measures and corroborating evidence when available.
    • Document prior treatment failures and detailed justification for use in the individual patient.
    Documentation Required

    Documentation must verify medically necessary indication and policy thresholds

    Documentation must support that the selected medically necessary indication and any stated size or clinical criteria are met when submitting CPT/ICD codes — include lesion size, number, GFR, and other policy thresholds as applicable.

    • Attach imaging reports showing lesion dimensions and number.
    • Include relevant labs (e.g., GFR) and notes documenting surgical risk or solitary kidney status when claimed.
    Documentation Required

    Imaging and biopsy documentation — use CE imaging and include biopsy results when performed

    Provide contrast-enhanced imaging and consider biopsy documentation for pre‑ and post‑procedure assessment; many series define ablation success by absence of contrast enhancement on follow‑up imaging and used biopsy selectively to confirm outcomes.

    • Include pre-procedure CE‑CT or CE‑MRI and post‑procedure CE imaging reports.
    • If biopsy was performed pre- or post‑ablation, include pathology results in the record.

    Background and Evidence Summaries

    Cryoablation is an image‑guided percutaneous, laparoscopic, surgical, endoscopic, or catheter‑based technique that destroys tissue by freezing. The procedure typically involves placement of one or more cryoprobes into the target lesion under imaging guidance (commonly CT or ultrasound), creation of an ice ball that encompasses the lesion, and one or more freeze‑thaw cycles to achieve tissue necrosis. Variants include contact cryotherapy, spray (noncontact) cryotherapy, and balloon/balloon‑assisted approaches for luminal organs.

    Common clinical applications described in the literature include treatment of small renal masses, pulmonary metastatic lesions in non‑surgical candidates, painful bone lesions and osteoid osteoma, certain dermatologic and mucosal lesions (e.g., cervical intraepithelial neoplasia, superficial skin cancers in selected settings), cardiac arrhythmia substrate ablation (cryoballoon pulmonary vein isolation for atrial fibrillation), and targeted palliation of symptomatic metastatic or benign lesions. Technique‑dependent risks include bleeding, infection, and procedure‑specific complications such as pneumothorax with lung procedures and potential thermal injury to adjacent critical structures.

    Definitions & Key Terms

    High-risk surgical candidate — definition and use in renal mass criteria
    Definition—high-risk surgical candidatePatients considered high-risk surgical candidates (used as an OR criterion for renal mass cryoablation) include those with substantial medical comorbidities or other factors making partial nephrectomy unacceptably risky
    Policy useBeing a high‑risk surgical candidate is an alternative criterion to permit cryoablation of a renal mass ≤4 cm
    Evidence contextMany renal cryoablation series enrolled elderly patients with significant comorbidity; authors note observation is an alternative in some older patients
    Cryosurgical ablation (prostate) — definition and context
    Cryosurgical ablation (prostate) — definitionA technique that destroys prostate tissue by freezing; recognized as an accepted management option for localized prostate adenocarcinoma (AUA statement) though long-term curative efficacy is not fully established
    Policy contextListed as a medically necessary option for localized prostate cancer (primary or salvage) in select patients
    Counseling implicationPatients should be informed about other definitive treatments and limits of long-term data
    Bronchoscopic cryotherapy / cryodebridement — definition
    Bronchoscopic cryotherapy / cryodebridement — definitionEndobronchial application of cryoprobes via flexible or rigid bronchoscopy to remove or debulk obstructing endobronchial material for palliation or airway recanalization
    Clinical outcomesSeries report high rates of airway patency restoration and symptom relief (e.g., partial restoration in ~90.6% of tumor-related cases)
    Typical settingOften used for malignant central airway obstruction when surgery is not feasible or as palliative therapy
    Percutaneous renal cryoablation — definition and description
    Percutaneous renal cryoablation — definitionCT-guided percutaneous insertion of cryoprobes into renal masses to create an ice ball that destroys tumor tissue; typically performed in patients who are poor surgical candidates
    Clinical featuresTechnique allows CT monitoring of ice formation beyond tumor margins with outpatient sedation in many series and reported technical success rates ~97%
    Typical tumor sizes reportedMean tumor sizes in series around 3.3 cm (range reported up to 7.3 cm) though policy coverage limits are ≤4 cm
    Percutaneous cryoablation — definition and short-term outcome context
    Percutaneous cryoablation — definitionA minimally morbid, image-guided technique to ablate small masses percutaneously (commonly CT-guided) with favorable short-term outcomes compared with laparoscopic approaches
    Short-term outcome contextShort-term follow-up shows similar recurrence and re-treatment rates to laparoscopic approaches; hemorrhage associated with multiple probes
    Use considerationOften reserved for patients who are elderly or have comorbidities making surgery higher risk
    Cryoballoon ablation — catheter-based cryoablation for atrial fibrillation
    Cryoballoon ablation — definitionA catheter-based cryoablation technique for pulmonary vein isolation in atrial fibrillation; randomized trial evidence (eg, STOP-AF) supports improved rhythm control versus drug therapy
    Guideline contextACC/AHA and HRS consensus statements recommend catheter ablation for symptomatic paroxysmal AF refractory to antiarrhythmic drugs and do not distinguish RF vs cryoballoon
    Typical indicationSymptomatic paroxysmal AF after failed anti-arrhythmic drug therapy or when drugs are not desired/tolerated
    Cervical intraepithelial neoplasia (CIN) — definition
    Cervical intraepithelial neoplasia (CIN) — definitionPre-malignant epithelial changes of the cervix categorized as CIN 1, 2, or 3; treated by local ablation or excision techniques
    Efficacy evidenceMeta-analysis reports high cure rates with cryotherapy: CIN1 94%, CIN2 92%, CIN3 85%
    Typical clinical useCryotherapy is effective, safe, and used widely including in low-resource settings
    Spray cryotherapy — definition
    Spray cryotherapy — definitionEndoluminal spray application of cryogen (eg, liquid nitrogen) to ablate mucosal lesions, described for esophageal carcinoma and airway applications
    Depth and device noteMetered Cryospray (MCS) delivers liquid nitrogen to central airways ablating epithelium to superficial depth (~0.1–0.5 mm)
    Safety concernsSome spray cryotherapy applications have reported serious complications (barotrauma, gas embolism) and are considered investigational for some airway uses
    Local adjuvants — definition and examples
    Local adjuvants — definitionAdjunctive surgical therapies used after intralesional curettage to decrease recurrence (examples: PMMA cement, phenol, cryotherapy, argon beam coagulation, high-speed burr)
    Clinical rationaleAdjuvants like bone cement permit immediate weight bearing and may reduce local recurrence; evidence from retrospective series is mixed
    Use contextLocal adjuvants are adjuncts to surgical tumor removal rather than standalone curative procedures
    Combined cryoablation and cementoplasty — definition
    Combined cryoablation & cementoplasty — definitionPercutaneous image-guided cryoablation of bone metastasis followed by cement injection to provide structural support and pain palliation
    Indication exampleUsed for large pelvic bone metastases (≥5.0 cm) refractory to medical pain control in patients not surgical candidates after multidisciplinary review
    Reported outcomesSeries report 100% technical success and symptom palliation with no immediate complications in selected cohorts
    Chronic rhinitis — definition
    Chronic rhinitis — definitionInflammation of the nasal passages with symptoms (congestion, rhinorrhea, sneezing, post-nasal drip) lasting at least 12 weeks
    Clinical measurementOutcomes commonly assessed with reflective Total Nasal Symptom Score (rTNSS), RQLQ, and NOSE scores
    Treatment contextPosterior nasal nerve cryoablation (PNN) studied for chronic rhinitis with randomized evidence showing superiority to sham at 90 days
    Responder (in Del Signore RCT) — definition as ≥30% reduction in rTNSS
    Responder definition (Del Signore RCT)Responder = at least a 30% reduction in the reflective Total Nasal Symptom Score (rTNSS) at 90 days
    Trial primary endpointPrimary endpoint in the randomized sham-controlled trial was proportion of responders at 90 days using this definition
    Use in authorizationResponder definition used to interpret PNN cryoablation effectiveness for prior authorization reviews
    Efficacy classification (osteoid osteoma trial) — NRS change categories
    Efficacy classification (osteoid osteoma trial)NRS change categories: Significantly effective (SE ≥5 or reached 0–2), Moderately effective (ME 2–4), Not effective (NE <2 or increase)
    Trial contextPhase I osteoid osteoma trial used these NRS-based classifications to categorize pain response after cryoablation
    Outcome timingMarked NRS reductions observed as early as 4 weeks and sustained to 1 year in the small phase I cohort
    Local tumor control (pulmonary cryoablation study) — outcome definition
    Local tumor control (pulmonary cryoablation) — definitionProportion of treated lesions without progression at specified time points (eg, 6 and 12 months) as assessed by imaging and RECIST-like criteria
    Assessment timingStudies report local control at 6 and 12 months (eg, 96.6% at 6 months and 94.2% at 12 months in de Baere et al.)
    Imaging basisRECIST-based measurements with 1-month post‑ablation baseline and subsequent interval CT/MRI to identify progression vs scar
    Technical success — definition and use in multiple series
    Technical success — definitionProcedure completed as intended with immediate procedural endpoints achieved (eg, ice ball coverage beyond tumor margins and absence of post‑ablation contrast enhancement)
    Reported ratesTechnical success reported as high (eg, 97% in Atwell et al. renal series; 100% technical success reported in multiple series)
    Use in reportingTechnical success often used as an immediate procedural endpoint distinct from longer‑term local control
    Intent — curative vs palliative intent definition
    Intent — definitionCurative intent = aim for complete ablation of tumor; Palliative/debulking intent = symptom control or structural support rather than curative resection
    Policy relevanceIntent (curative vs palliative) is recorded in studies and influences patient selection and documentation for authorization
    ExamplesCombined cryoablation + cementoplasty for large pelvic lesions is typically palliative; renal cryoablation for small RCC may be curative intent in select patients
    Oligometastatic pulmonary disease — definition used in trials
    Oligometastatic pulmonary disease — definitionLimited number of lung metastases (commonly 1–5 or 1–6 lesions) with maximal lesion diameters generally up to ~3.5 cm as used in multiple prospective studies
    Trial enrollment specificsKey trials enrolled patients with 1–5 or 1–6 metastases and maximal lesion diameters ≤3.5 cm
    Outcome implicationsBest local control and fewer complications observed in patients with fewer and smaller metastases
    Osteoid osteoma — definition
    Osteoid osteoma — definitionA benign bone tumor with a small radiolucent nidus and reactive sclerosis, typically causing nocturnal pain relieved by NSAIDs; amenable to percutaneous ablation
    Typical nidus sizeReported mean nidus sizes in trials ~5–6 mm; cryoablation demonstrates marked pain relief
    Treatment pathwayPercutaneous cryoablation used when NSAID/salicylate therapy fails or when surgery is not preferred
    RECIST — definition and use as response criteria
    RECIST — definitionResponse Evaluation Criteria in Solid Tumors; used to assess tumor response with a 1-month post‑ablation baseline and measurement of ablation zone/scar versus progression
    ApplicationRECIST-based assessments applied to small lesion cryoablation studies with serial CT/MRI evaluations
    Interpretation nuanceResidual scar may be measured as complete response rather than disappearance of treated tumor due to post‑ablation involution
    Local tumor control / local recurrence-free survival — outcome measure definitions
    Local tumor control / local recurrence-free survival — definitionOutcome measures representing absence of progression at treated site(s) at specified time points (eg, 6, 12, 24 months) usually assessed by imaging
    Reported metricsStudies report local control rates at 6 and 12 months and RFS at 12 and 24 months (eg, Callstrom: 85.1% at 12 mo, 77.2% at 24 mo)
    Use in authorizationDocumented local control outcomes inform expected effectiveness and post‑procedure follow-up recommendations
    cryoanalgesia / cryoneuroablation / cryoneurolysis — definition
    Cryoanalgesia / cryoneuroablation / cryoneurolysis — definitionMinimally invasive application of extreme cold to peripheral nerves to disrupt conduction and provide long‑term pain relief for focal neuropathic or nociceptive targets
    Clinical applicationsUsed for articular facet syndromes, knee pain, sacroiliac pain, intercostal nerve analgesia; reported improvements in VAS and function in small series
    Safety noteOutcomes and durability vary; evidence includes retrospective series and small trials
    percutaneous image-guided cryoablation (PCA) — definition
    Percutaneous image-guided cryoablation (PCA) — definitionImage-guided placement of cryoprobes (commonly CT-guided) to freeze and ablate target lesions for tumor control or palliation, sometimes combined with cementoplasty for structural support
    Technical featuresUses multiple freeze‑thaw cycles and intra-procedural imaging to monitor ice ball formation and margin coverage
    Use contextsApplied across renal, pulmonary, musculoskeletal, and soft‑tissue lesions in selected patients
    Technical success (cryoablation) — definition from VM study
    Technical success (cryoablation) — study definitionComplete coverage of the lesion by an iceball and absence of immediate post‑ablation contrast enhancement; used as an immediate procedural endpoint
    VM study exampleFujiwara et al reported technical success as iceball coverage in 8 of 9 VM patients
    Distinction from long-term controlTechnical success does not necessarily predict long‑term local control which requires follow-up imaging
    IBTR — definition used in ICE3 trial
    IBTR — definitionIpsilateral breast tumor recurrence as used as the primary endpoint in the ICE3 trial evaluating breast cryoablation
    Trial contextICE3 reported 5‑year IBTR of 4.3% in eligible cohort treated with cryoablation
    Use implicationIBTR used to measure local effectiveness of cryoablation in breast cancer studies and regulatory submissions
    Biologically low-risk breast cancer — eligibility definition for FDA-authorized indication
    Biologically low-risk breast cancer — definitionUnifocal tumor ≤1.5 cm, ER+, PR+, HER2‑, Ki‑67 <15% and/or genomic testing indicating low risk, infiltrating ductal carcinoma, and node‑negative (as per FDA authorization context)
    Regulatory noteProSense received FDA premarket authorization for patients ≥70 years with biologically low‑risk tumors when combined with endocrine therapy (Oct 3, 2025)
    Trial eligibilityICE3 enrolled women ≥60 with uni-focal, US‑visible invasive ductal carcinoma ≤1.5 cm, grade 1–2, HR+, HER2‑
    Rosai-Dorfman disease (RDD) — definition
    Rosai-Dorfman disease (RDD) — definitionA rare non‑Langerhans cell histiocytosis with histiocyte overgrowth, often causing massive cervical lymphadenopathy and possible extranodal involvement
    Clinical variabilityDisease may present as nodal or extranodal RDD (skin, bone, CNS, airways); treatment varies by presentation
    Cryoablation contextCryoablation discussed in background as a potential local therapy in select extranodal disease sites
    Metered Cryospray (MCS) — definition and device description
    Metered Cryospray (MCS) — definitionA device‑delivered liquid nitrogen application to central tracheobronchial airways ablating abnormal epithelium to a shallow depth (≈0.1–0.5 mm)
    Therapeutic rationaleAims to remove goblet‑cell hyperplastic epithelium to permit regeneration of healthier mucosa and reduce mucus hypersecretion in chronic bronchitis
    Study contextSmall studies of MCS report symptom and QOL improvements but durability and larger RCT evidence remain limited
    Metallic Supra-structured Cryo-Nanocatalyst (MSCN) — definition
    MSCN — definitionMetallic supra‑structured cryo‑nanocatalyst (MSCN): a nano‑structured agent that increases ice nucleation sites and can carry therapeutic agents to enhance cryoablation efficacy and immunogenic necroptosis in preclinical models
    Preclinical roleDesigned to elevate freezing point, enhance ice formation, and potentiate immunogenic cell death when combined with checkpoint blockade in models
    StatusExperimental/preclinical adjunct to cryoablation; not established in clinical practice
    Cryoablation — general definition across modalities
    Cryoablation — general definitionA percutaneous, laparoscopic, surgical, endoscopic, or image‑guided technique that destroys tissue by freezing and is applied across multiple organs and indications
    Modalities coveredIncludes percutaneous cryoablation, bronchoscopic cryotherapy, cryoballoon catheter ablation, spray cryotherapy, and surgical cryoablation techniques
    Clinical considerationsUsed for curative and palliative intents depending on indication, lesion size/number, and patient comorbidity

    Policy Revision History

    1995-12-06policy_effective

    Policy effective date recorded for Aetna Cryoablation policy number 0100.

    2025-10-03device_authorization

    ProSense (IceCure Medical) cryoablation received FDA premarket marketing authorization for treatment of low-risk breast cancer in women aged 70 and above.

    2026-08-04policy_reviewLatest

    Most recent policy review completed (last review date).

    2027-01-28next_scheduled_review

    Next scheduled policy review date as documented in the policy metadata (Part 15 of 15).